オプションチェーンは、Immuneeringの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Immuneeringの市場センチメントを評価します。.

Immuneering (NASDAQ:IMRX) 株価情報, オプションチェーン

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Immuneering Corporation - Class A Common Stock

Immuneering Corp

Each Unit Consisting Of One Common Share And One Warrant; Warrants Exercisable Immediately With $0.87 Exercise Price, Expiring In Five Years

News

Offerings

NAYA

NAYA Biosciences Announces Public Offering Of Up To 14.94M Units Priced At $0.87 Per Unit

Premium Experience Catching Fire: Closing out a year of consistent multi-million-dollar monthly sales, VENU continues to redefine exclusive ownership opportunities for discerning investors
Venu Holding Corporation ("VENU" or "The Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VENU#NYSE">VENU</a>), a leading premium hospitality and live entertainment company built by music fans for music fans, finished the year by closing over $11 million in luxury fire pit suite sales for the month of December, further extending VENU's 12 month multi-million-dollar monthly closing streak for entity-based ownership opportunities. Fire Pit Suite sales surged to an impressive $77.7 million in 2024 and are projected to exceed $200 million in 2025.

Guidance

VENU

Venu Holding Corp. Surpasses $11M in December Fire Pit Suite Sales, $77.7M Annually; Projects $200M in 2025

Cantor Fitzgerald analyst Andres Sheppard reiterates Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) with a Neutral and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

LCID

Cantor Fitzgerald Reiterates Neutral on Lucid Gr, Maintains $3 Price Target

WIIM

LFWD

Lifeward shares are trading lower after the company announced a $5 million registered direct offering.

DNLI

Denali Therapeutics shares are trading lower after the company announced topline results for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral sclerosis did not meet its primary endpoint.

<ul>
<li>Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin</li>
<li>Pilot study by National Cancer Institute's Cancer Screening Research Network will inform design of future research evaluating use of multi-cancer detection blood tests to screen for cancer</li>
</ul>
Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), a leading precision oncology company, today announced the National Cancer Institute (NCI) has selected the company's Shield&#x2122; multi-cancer detection (MCD) test for use in its Vanguard study, which will address the feasibility of using MCD tests in future clinical trials related to cancer screening. MCD tests are blood tests that can screen for several types of cancers simultaneously.
In February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN), which is funded by the NCI, part of NIH, to evaluate emerging cancer screening technologies, including MCD tests. The network will support research to investigate how to identify and diagnose cancers earlier, when they may be easier to treat.
As an initial effort, CSRN is launching the Vanguard Study, a four-year pilot study that will enroll up to 24,000 people to inform the design of a much larger randomized controlled trial evaluating the use of MCD tests for cancer screening. In its studies, the network aims to reach diverse populations, including underserved populations, that are receiving routine care in a variety of health care settings.

Biotech

General

Guardant Health Announces Shield Multi-Cancer Detection Test Selected for National Cancer Institute's Vanguard Study; Pilot Study to Enroll 24K Participants and Inform Future Research on MCD Tests for Cancer Screening

GFL Environmental Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) shares surged on Tuesday after the company disclosed an agreement to sell interest in its Environmental Services business to Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and BC Partners. The deal values the Environmental Services business at <a target="_blank" href="https://www.benzinga.com//node/42838942" rel="noreferrer noopener">an enterprise value of&nbsp;C$8.0 billion ($5.6 billion).</a>
GFL will retain a&nbsp;C$1.7 billion&nbsp;equity interest in the Environmental Services business and expects to realize cash proceeds from the sale of approximately&nbsp;C$6.2 billion&nbsp;net of the retained equity and taxes.
As per the deal, GFL will retain a 44% equity interest in its Environmental Services business, with the Apollo Funds and BC Funds each holding a 28% equity stake.
GFL plans to use up to C$3.75 billion of the net proceeds from the transaction to repay debt, with up to C$2.25 billion allocated for share repurchases. The remainder will be used for transaction fees and general corporate purposes.
The transaction is expected to close in the first quarter of 2025, subject to customary closing conditions.
Patrick Dovigi, Founder and Chief Executive Officer of GFL, said, &#8220;The transaction will allow us to materially delever our balance sheet which will accelerate our path to an investment grade credit rating.&#8221;
&#8220;The transaction allows us to monetize the Environmental Services business in a tax efficient manner while retaining an equity interest that will allow us to participate in what we expect to be continued value creation from these high-quality assets. In addition, GFL will maintain an option, not an obligation, to repurchase the Environmental Services business within five years of closing.&#8221;
The company plans to provide more details on the transaction&#8217;s financial impact when it <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">reports its 2024 full-year results in February.</a>
Investors can gain exposure to GFL via TCW Transform Supply Chain ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPP#NYSE">SUPP</a>).
Price Action: GFL shares are up 3.57% at $45.59 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/content/42635812/opal-fuels-ceo-on-steering-the-future-of-renewable-natural-gas" target="_blank" rel="noreferrer noopener">Opal Fuels CEO on Steering the Future of Renewable Natural Gas</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Buybacks

Asset Sales

Movers

SUPP

GFL Environmental To Sell Stake In Environmental Services Business: Debt Reduction & Stock Buyback On The Cards

Cantor Fitzgerald analyst Brett Knoblauch reiterates Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Overweight and maintains $35 price target.

Cantor Fitzgerald Reiterates Overweight on Hut 8, Maintains $35 Price Target

<ul>
<li>A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM) detected a structural variant that was missed by karyotyping and non-informative by FISH, which they classified as a PML::RARA fusion known to occur in acute promyelocytic leukemia (APL) &nbsp;</li>
<li>The researchers reported that APL, an aggressive subtype of acute myelogenous leukemia (AML), responds well to treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) classes of targeted therapies but that in about 13% of cases of APL, conventional cytogenetics fails to identify the variant(s) that indicate(s) these treatment &nbsp;</li>
<li>Identification of this PML::RARA fusion variant by OGM is consistent with previously reported findings which show that OGM can detect variants found by standard cytogenetics and can also find additional variants that are missed by these techniques &nbsp;</li>
</ul>
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) today announced a publication from the Johns Hopkins University School of Medicine in Genes showing that optical genome mapping (OGM) identifies a variant in an aggressive form of acute myelogenous leukemia (AML) known as acute promyelocytic leukemia, or APL. This variant is often missed by conventional cytogenetic techniques.

BNGO

Bionano Announces Publication Showing That OGM Identifies Variant That Indicates Use Of Proven Therapy In Acute Promyelocytic Leukemia

Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) will release its fourth-quarter financial results before the <a href="https://www.benzinga.com/quote/C/earnings" target="_blank" rel="noopener">opening bel</a><a href="https://www.benzinga.com/quote/C/earnings">l on Wednesday, Jan. 15.</a>
Analysts expect the New York-based company to report quarterly earnings at $1.21 per share, up from 84 cents per share in the year-ago period. Citigroup projects quarterly revenue of $19.42 billion, compared to $17.44 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, Barclays upgraded the stock from Equal-Weight to Overweight and raised its price target from $70 to $95.
With the recent buzz around Citigroup, some investors may be eyeing potential gains from the company's dividends too. As of now, Citigroup offers an annual dividend yield of 3.08%, which is a quarterly dividend amount of 56 cents per share ($2.24 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $194,870 or around 2,679 shares. For a more modest $100 per month or $1,200 per year, you would need $39,989 or around 536 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.24 in this case). So, $6,000 / $2.24 = 2,679 ($500 per month), and $1,200 / $2.24 = 536 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
C Price Action: Shares of Citi gained 2.5% to close at $72.74 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42820522/jpmorgan-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">JPMorgan Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo: Shutterstock

Earnings

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From Citigroup Stock Ahead Of Q4 Earnings

Roth MKM analyst Mike Niehuser maintains Perpetua Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) with a Buy and raises the price target from $15 to $19.

PPTA

Roth MKM Maintains Buy on Perpetua Resources, Raises Price Target to $19

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target.
Under the terms of the license agreement, Immunome will&nbsp;be responsible for the research, development, manufacturing and commercialization of products&nbsp;incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for&nbsp;future development and commercial milestone payments, as well as royalties.

Contracts

IMNM

Hummingbird Bioscience Licenses Monoclonal Antibodies To Immunome For Exclusive Worldwide Use, Receives Upfront Payment And Potential Milestone Payments, Royalties

GFL Environmental shares are trading higher after the company announced the sale of a stake in its services business valued at C$8B and will retain a 44% equity interest.

Roth MKM analyst Darren Aftahi reiterates FuboTV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) with a Neutral and raises the price target from $2 to $4.75.

FUBO

Roth MKM Reiterates Neutral on FuboTV, Raises Price Target to $4.75

Cantor Fitzgerald analyst Brett Knoblauch reiterates Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) with a Overweight and maintains $11 price target.

CIFR

Cantor Fitzgerald Reiterates Overweight on Cipher Mining, Maintains $11 Price Target

The Agreement provides exclusivity in negotiations to the counterparty for a period of 105 Business Days ("Exclusivity Period") and cumulative payments of up to $5 million to Hallador Power Company, LLC, with $1 million due in January, $2 million of payments due in March, if the parties have not satisfied certain conditions precedent to the proposed transaction, and an additional $2 million in June if such conditions precedent have not been satisfied by the end of the Exclusivity Period. The parties will use the Exclusivity Period to finalize selection of a utility partner and to negotiate and complete other definitive agreements related to the proposed transaction. If the Company is successful in executing definitive agreements and once the transaction commences, it is expected to contract the majority of the Company's energy and capacity at prices higher than the forward curve for more than a decade.
 &nbsp;

HNRG

Hallador Energy Signs Conversion Transaction Commitment Agreement With A Data Center Developer, Which Provides Exclusivity In Negotiations For 105 Days And Cumulative Payments Of Up To $5M

PRMB

Primo Bands shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a price target of $40. Also, RBC Capital raised its price target from $35 to $38.

Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging with Telomir-1.
The study was conducted in nematodes (C. elegans) with a mutation in the wrn-1 gene, which is equivalent to a gene in humans associated with Werner Syndrome (a form of Progeria). Compared to normal (wild-type) nematodes, those with wrn-1 depletion showed a significantly reduced mean and median lifespan. Utilizing advanced in vivo microfluidic technology, the study demonstrated lifespan restoration and normalization of accelerated agingeffects in wrn-1-mutated nematodes treated with Telomir-1. The treatment effectively restored longevity to levels not significantly different from normal animals. These effects included an extended healthy lifespan and the normalization of several physiological parameters, such as movement velocity and tail amplitude.

TELO

Telomir Pharmaceuticals Announces Potentially Groundbreaking Findings From A Preclinical Progeria Lifespan Study Conducted In Collaboration With Nagi Bioscience SA. Utilizing C. Elegans Models, In Which The Study Demonstrated Restoration Of Shortened Lifespan And Normalization Of Accelerated Aging With Telomir-1

D. Boral Capital analyst Jesse Sobelson maintains American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) with a Buy and maintains $4 price target.

AREC

D. Boral Capital Maintains Buy on American Res, Maintains $4 Price Target

Median overall survival improvement expected to exceed one year
First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
RARITAN, N.J., Jan. 7, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced positive topline results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study, evaluating RYBREVANT&#xAE; (amivantamab-vmjw) plus LAZCLUZE&#x2122; (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The chemotherapy-free combination regimen met the final pre-specified secondary endpoint of OS and demonstrated clinically meaningful and statistically significant improvement in OS versus the current standard of care osimertinib. Improvement in median OS is expected to exceed one year.

Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen With A Survival Benefit Over Current Standard Of Care In First-line Treatment Of EGFR-Mutated Lung Cancer

Ami Fadia, an analyst from Needham, maintained the Buy rating on Immuneering (IMRX – Research Report). The associated price target remains the same...

Immuneering's Promising Outlook: Strong Clinical Progress and Financial Stability

Immuneering (IMRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeffrey Hung from Mo...

Cautious Hold Recommendation on Immuneering Amid Promising Developments and Financial Uncertainties

Immuneering GAAP EPS of -$0.49

Immuneering Corp. Class A ( ($IMRX) ) has released its Q3 earnings. Here is a breakdown of the information Immuneering Corp. Class A presented to i...

Immuneering Corp. Reports Q3 Loss, Highlights Progress

Morgan Stanley analyst Jeffrey Hung downgraded Immuneering (IMRX) to Underweight from Equal Weight and instituted a base case range of $1-$5 from $...

Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley upgrades PTC, cuts Immuneering, Amicus

Discover today's top stock opportunities with our 4-pillar strategy, combining catalysts, sentiment, fundamentals, and technicals to highlight 6 must-watch trades before the market opens.

Top Trade Picks Of The Day: Don't Miss These Market Movers

The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves.

Mastering Market Chaos: StoryTrading's Top 5 Stocks You Can't Ignore

Immuneering (IMRX) announced a positive data update from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104, as w...

Immuneering announce data update from Phase 2a trial of IMM-1-104

Immuneering expands lead program after favorable mid-stage data in pancreatic cancer

BYRN

FOLD

IMCR

IMRX

MARA

MIND

PTCT

RCAT

Health Care

Press Releases

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Biotech Surges Following Positive Phase 2a Observations

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

Immuneering Launches Pancreatic Cancer Advisory Board

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Comments

Immuneering

Immuneering (IMRX) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル